KLRD1 and neoplasm: Favorable clinical responses in a randomized phase II clinical trial in patients with advanced NSCLC could be attributed to an increased prevalence of activated CD94+ NK cells (Multhoff et al., 2020) recognizing mHsp70+ tumor cells (Gross et al., 2003).